Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus VIBATIV.
MYCHEL vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
Adults: 200 mg orally twice daily for 14 days.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic